tradingkey.logo

Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6

ReutersJun 16, 2025 11:42 AM

- Simcere Pharmaceutical Group Ltd 2096.HK:

  • NEXTCURE AND SIMCERE ZAIMING ANNOUNCE STRATEGIC PARTNERSHIP FOR A NOVEL ANTIBODY-DRUG CONJUGATE TARGETING CDH6

  • NEXTCURE INC - GAINS GLOBAL RIGHTS TO SIM0505 EXCLUDING GREATER CHINA

  • NEXTCURE INC - U.S. PHASE 1 CLINICAL TRIAL FOR SIM0505 TO BEGIN Q3 2025

  • NEXTCURE INC - SIMCERE ZAIMING ELIGIBLE FOR PAYMENTS UP TO $745M AND ROYALTIES

  • NEXTCURE INC - INITIAL PHASE 1 CLINICAL DATA EXPECTED IN FIRST HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI